Reactivated HSV-1 disease in immune compromised hosts

免疫受损宿主中重新激活的 HSV-1 疾病

基本信息

  • 批准号:
    6634707
  • 负责人:
  • 金额:
    $ 30万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-04-01 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Provided by the Applicant) Herpes virus infection is a very common recurrent health problem in humans, especially immuno suppressed individuals. After resolution of primary infection, a state of latency develops that persists until death. Environmental stimuli such as UV lead to periodic recrudescence of disease. The investigators have recently developed a powerful murine model of reactivated HSV disease of epithelium that is stimulated by a minimum UV exposure. This very closely mimics HSV epithelium disease in man, permitting study of cutaneous HSV-1 reactivation in a relevant experimental system. The studies proposed in this application will use this model to test the hypothesis that reactivated HSV-1 disease is due to a disruption in local cytokine balance, and disease resolution requires local cutaneous immunologic changes. They propose to study the immunopathology of HSV disease reactivation and suggest new treatments and vaccine strategies. They hypothesize that UV exposure results in secretion of soluble factors by keratinocytes that ultimately alter the TH1/TH2 balance which induces HSV from reactivation. Lack of CD4 responses in CD4 depleted animals then permit severe and prolonged disease. They propose that modulation of local immune factors including IL-12 and IFN-gamma alter the reactivation process and that differences of components of the local immune systems impact susceptibility to HSV-1 infection. Studies will be done in immune competent mice and in mice depleted of CD4 which yields reactivated HSV disease in a manner very similar to human HSV disease in HIV infected hosts. Specifically, they will characterize the immune response to HSV-1 at the local cutaneous level and to define the context of interplay of cytokines and immune cells during reactivated cutaneous HSV-1 disease; determine the role of infiltrating T lymphocytes in primary and reactivated disease in normal versus immune compromised models; and determine efficacy of genomic vaccine candidates in prevention of primary infection and in attenuation of reactivated disease.
描述:(由申请人提供)疱疹病毒感染是一种非常严重的 人类常见的复发性健康问题,尤其是免疫抑制 个体原发感染消退后,出现潜伏状态 直到死亡。环境刺激,如紫外线,导致周期性 疾病复发。研究人员最近开发了一种强大的 由一种刺激的上皮再活化HSV疾病的鼠模型 最小紫外线暴露。这非常类似于人类的HSV上皮疾病, 允许在相关实验中研究皮肤HSV-1再活化 系统本申请中提出的研究将使用该模型来测试 HSV-1疾病的再活化是由于局部 细胞因子平衡和疾病的解决需要局部皮肤免疫学 变化他们建议研究HSV疾病再激活的免疫病理学 并提出新的治疗方法和疫苗策略。他们假设紫外线 暴露导致角质形成细胞分泌可溶性因子, 最终改变TH 1/TH 2平衡,诱导HSV再活化。缺乏 在CD 4耗竭的动物中, 疾病他们提出,包括IL-12在内的局部免疫因子的调节 和IFN-γ改变了再激活过程, 局部免疫系统的功能影响对HSV-1感染的易感性。研究 将在免疫活性小鼠和CD 4耗竭小鼠中进行, 以与HIV中的人类HSV疾病非常相似的方式重新激活HSV疾病 感染的宿主具体来说,他们将描述免疫反应, HSV-1在局部皮肤水平,并定义的相互作用的背景下, 再活化皮肤HSV-1疾病期间的细胞因子和免疫细胞; 确定浸润性T淋巴细胞在原发性和再活化中的作用 在正常与免疫受损模型中的疾病;并确定 基因组疫苗候选物在预防原发性感染和 减少再活化的疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Diane E Goade其他文献

Diane E Goade的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Diane E Goade', 18)}}的其他基金

CLINICAL TRIAL: A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM
临床试验:III 期双盲、安慰剂对照长期试验
  • 批准号:
    7952025
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:
INVESTIGATION OF THE NATURAL HISTORY OF WEST NILE VIRUS INFECTION, OR AT RISK
西尼罗河病毒感染或处于危险中的自然史的调查
  • 批准号:
    7952032
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:
CLINICAL TRIAL: A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM
临床试验:III 期双盲、安慰剂对照长期试验
  • 批准号:
    7716573
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:
CLINICAL TRIAL: INVESTIGATION OF THE NATURAL HISTORY OF WEST NILE VIRUS INFECTIO
临床试验:西尼罗河病毒感染自然史的调查
  • 批准号:
    7716562
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:
A PHASE I/KK RANDOMIZED PLACEBO-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFIC
评估安全性和有效性的 I/KK 期随机安慰剂对照试验
  • 批准号:
    7606862
  • 财政年份:
    2006
  • 资助金额:
    $ 30万
  • 项目类别:
A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM THERAPY OF
长期治疗的 III 期双盲、安慰剂对照试验
  • 批准号:
    7606878
  • 财政年份:
    2006
  • 资助金额:
    $ 30万
  • 项目类别:
A PHASE I/KK RANDOMIZED PLACEBO-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFIC
评估安全性和有效性的 I/KK 期随机安慰剂对照试验
  • 批准号:
    7205310
  • 财政年份:
    2004
  • 资助金额:
    $ 30万
  • 项目类别:
A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM THERAPY OF
长期治疗的 III 期双盲、安慰剂对照试验
  • 批准号:
    7205329
  • 财政年份:
    2004
  • 资助金额:
    $ 30万
  • 项目类别:
Reactivated HSV-1 disease in immune compromised hosts
免疫受损宿主中重新激活的 HSV-1 疾病
  • 批准号:
    6858773
  • 财政年份:
    2001
  • 资助金额:
    $ 30万
  • 项目类别:
Reactivated HSV-1 disease in immune compromised hosts
免疫受损宿主中重新激活的 HSV-1 疾病
  • 批准号:
    6516663
  • 财政年份:
    2001
  • 资助金额:
    $ 30万
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了